Mangoceuticals, Inc. Stock

Equities

MGRX

US56270V1061

Healthcare Facilities & Services

Market Closed - Nasdaq 16:00:00 2024-06-20 EDT 5-day change 1st Jan Change
0.3499 USD +16.56% Intraday chart for Mangoceuticals, Inc. +2.88% +26.36%
Sales 2022 0.01 0.01 Sales 2023 0.73 1 Capitalization 5.83M 7.97M
Net income 2022 -2M -2.74M Net income 2023 -9M -12.31M EV / Sales 2022 * -
Net cash position 2022 330K 451K Net cash position 2023 610K 835K EV / Sales 2023 7,129,952 x
P/E ratio 2022 *
-
P/E ratio 2023
-0.48 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 55.58%
More Fundamentals * Assessed data
Dynamic Chart
1 day+16.56%
1 week+2.88%
Current month-11.10%
1 month+38.30%
3 months+74.95%
6 months+20.66%
Current year+26.36%
More quotes
1 week
0.29
Extreme 0.29
0.38
1 month
0.29
Extreme 0.29
0.59
Current year
0.14
Extreme 0.143
1.12
1 year
0.14
Extreme 0.143
1.99
3 years
0.14
Extreme 0.143
4.37
5 years
0.14
Extreme 0.143
4.37
10 years
0.14
Extreme 0.143
4.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 21-09-30
Director of Finance/CFO 60 22-09-30
Chief Operating Officer 38 22-09-30
Members of the board TitleAgeSince
Director/Board Member 52 22-10-13
Chief Executive Officer 45 21-09-30
Director/Board Member 44 22-10-13
More insiders
Date Price Change Volume
24-06-20 0.3499 +16.56% 1,448,326
24-06-18 0.3002 +0.10% 504,404
24-06-17 0.2999 -6.25% 471,807
24-06-14 0.3199 -5.94% 509,983
24-06-13 0.3401 -8.18% 700,596

Delayed Quote Nasdaq, June 20, 2024 at 04:00 pm

More quotes
Mangoceuticals, Inc. is primarily focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. The Company has developed and is commercially marketing a new brand of erectile dysfunction (ED) products under the brand name Mango and a brand of hair loss products under the brand name Grow. These products are produced at a compounding pharmacy using a proprietary combination of United States Food and Drug Administration (FDA) approved ingredients and are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. It is marketing and selling these branded ED and hair loss products exclusively online via its Website at www.MangoRx.com. Its customer platform connects consumers to licensed healthcare professionals through its Website for the provision of care via telehealth. It also owns a global patent portfolio of oral solution.
More about the company